Dr. Fackler joined Alvogen in 2018 and directs both their clinical and non-clinical studies. Prior to Alvogen, he was at Merck Research Laboratories from 2010 to 2018 managing a clinical group to support development of second-generation products such as new fixed dose combinations, products with improved PK profiles, and those with new delivery routes. He also worked at Teva Pharmaceuticals as Vice President Generic R&D, 1998 to 2010, Springborn Laboratories, and Johnson Matthey. He has served on the FDA Advisory Committee for Clinical Pharmacology and has been on two USP expert committees.
Paul Fackler Vice President, Clinical R&D at Alvogen